On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $64.63 which represents a slight increase of $1.49 or 2.36% from the prior close of $63.14. The stock opened at ...
The Motley Fool on MSN1d
Is Viking Therepautics a Buy Now?Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...
Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing ...
Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Oppenheimer analyst Jay Olson maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of ...
GlobalData on MSN1d
Viking stock fluctuates amid manufacturing concerns with obesity pillViking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback